Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Ropivacaine Hcl Articles

Abraxis completes purchase of AstraZeneca brands

3 July 2006

AstraZeneca and Abraxis sign US Abraxane co-promotion deal for $200M

8 May 2006

AstraZeneca's Naropin gets new use in EU

22 December 2003

AstraZeneca wins new label for Naropin

9 November 2000

AstraZeneca updates on anesthetics

8 June 2000

AstraZeneca gets EU approval as Chiroscience prepares to reap the reward

2 March 1999

Canadian expansion for Astra AB

25 January 1999

Chirocaine long-acting local anesthetic recommended for US approval

13 January 1999

Chirocaine Approved In First Market

16 December 1998

Highlights Of Astra's Pipeline Presentation

30 January 1998

Strength In Astra's R&D To Cushion Losec's Demise?

9 June 1997

Currency Exchange Affects 1996 Sales At Astra

24 February 1997

UK Launch For Astra's Ropivacaine

27 January 1997

Record Number Of New Chemical Entities In 1996

20 January 1997

Six Major Launches Planned For 1997 As Part Of Astra's Growth Strategy

23 December 1996

Astra USA's Naropin Cleared In USA

7 October 1996

Astra Strengthens R&D With Increased Spending

4 December 1995

33% Sales Growth For Astra

13 November 1995

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS